Stereotaxis, Inc. (STXS)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$1.390.00%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · STXS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -48.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 37.1% |
Growth built into the price is above our model estimate.
The price assumes 86.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 26 industry peers · Company calendar date is not available
STXS — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition On August 11, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein. Forward-Looking Statements and Additional Information Statements are made herein or incorporated herein that are “forward-looki…
Why it matters: If management score goes up, it may show more confidence and better execution.
Supportive ifManagement score increases by more than 5 points in the next quarter.
Worry ifManagement score declines or stays the same in the next quarter.
Why it matters: A bigger operating loss could mean trouble in managing costs during the change.
Worry ifQ2 operating loss was over $6 million. This shows issues with cost management.
Less concerning ifOperating loss was under $6 million. This suggests better cost control.
Why it matters: If valuation changes from 'inexpensive', it may show how the market thinks.
Watch forValuation label changes to 'expensive' in the next earnings report.
Also watch forThe valuation label will stay 'inexpensive' in the next earnings report.
Why it matters: A successful integration is important for Stereotaxis. It helps them offer more products and reach more customers.
Supportive ifManagement says they met their goals after buying Robocath. This happened in the first six months.
Worry ifThey report problems with integration. This has caused delays and issues in operations.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $564 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,471 loss on $10,000 · 64.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A recovery in Q2 revenue would indicate a positive trend after the decline in Q1. It could boost investor confidence.
Watch forQ2 revenue reported above $7 million.
Also watch forQ2 revenue reported below $6 million.
Why it matters: Reaching this production level would indicate strong demand and support revenue growth.
Supportive ifProduction of 500 MAGiC catheters per month was reported. This meets demand.
Worry ifProduction is below 500 units per month. This shows supply problems.
Why it matters: If healthcare revenue growth speeds up, it could help Stereotaxis's market position.
Supportive ifHealthcare revenue growth speeds up to more than 10% year over year.
Worry ifHealthcare revenue growth slows down below 10% year over year.
Why it matters: Achieving this target would confirm strong demand for new products and growth momentum.
Supportive ifRecurring revenue in Q3 exceeds $7 million as expected.
Worry ifRecurring revenue in Q3 is below $6.5 million. This shows weaker demand.
Why it matters: This would show a recovery in system sales. It would support the new product plan.
Supportive ifSystem revenue in Q3 exceeds $3 million as projected.
Worry ifSystem revenue in Q3 is below $2 million. This shows ongoing sales problems.
Why it matters: Hitting this target would show a big improvement in financial health.
Supportive ifManagement confirms cash flow became profitable in the first half of 2027.
Worry ifCash flow stays negative past mid-2027. This shows continued financial issues.